The overlap between Essential tremor and Parkinson disease

Algarni, Musleh; Fasano, Alfonso

doi:10.1016/j.parkreldis.2017.07.006

Cited by 76 publications

(55 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We focused here on RBD in part because it is the strongest prodromal marker of α‐synucleinopathies, and we wanted to explore the idea that ET‐plus may be a prediagnostic phase of PD or other neurodegenerative disease . We found that pRBD was present in 20.5% of ET‐plus patients and 8.3% of ET patients, and these prevalence were higher than the prevalence of RBD in the general Chinese population (2.70%) or the prevalence of pRBD in the general population (5.5%) .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical characteristics of patients with essential tremor or essential tremor plus

et al. 2020

View full text Add to dashboard Cite

Background The International Parkinson and Movement Disorder Society introduced the category of essential tremor (ET)‐plus in its new ET classification scheme, but how the clinical correlates of ET‐plus differ from those of “pure” ET is unclear. By comparing the clinical characteristics of ET and ET‐plus patients, we expect to better understand the impact and invoked questions of the new classification on clinical practice. Methods We reviewed the medical records of 280 ET syndrome patients in an ongoing cross‐sectional study in a Chinese population and reclassified them according to the new criteria. Clinico‐demographic characteristics were compared between ET and ET‐plus patients. Risk factors of diagnosis of ET‐plus were explored using logistic regression. Results A total of 121 patients (50.8%) were reclassified as having ET and 117 as having ET‐plus. ET‐plus group was significantly older at tremor onset, less educated, and more likely to have cranial tremor, depression symptom, anxiety symptom, and probable REM sleep behavior disorder. ET‐plus group also showed more severe upper limb tremor and cognition impairment. Regression analysis identified four independent risk factors associated with ET‐plus: late tremor onset (OR 3.04, 95%CI 1.60‐5.79), less educated (OR 0.91, 95%CI 0.85‐0.97), severe upper limb tremor (OR 2.46, 95%CI 1.30‐4.62), and presence of cranial tremor (OR 2.30, 95%CI 1.20‐4.41). Conclusions The new classification scheme emphasized that ET syndrome is heterogeneous. ET‐plus cannot be seen as a subtype or a diagnosis of ET syndrome, but rather as a placeholder, representing an area of current scientific uncertainty.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Their findings indicate that ET‐plus may mainly represent an advanced stage of ET . In some other point of view, ET‐plus may be a prediagnostic phase of neurodegenerative disease such as Parkinson's disease (PD) …”

Section: Introductionmentioning

confidence: 99%

Clinical characteristics of patients with essential tremor or essential tremor plus

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In general practice, propranolol may be prescribed for coronary heart disease, hypertension, variceal hemorrhage prophylaxis, tachyarrhythmia and palpitations, migraine headache prophylaxis, and for controlling tremor and essential tremor. Among these, only migraine and essential tremor were found to be associated with increased risk of PD. To account for confounding by indication by these 2 risk factors, we have adjusted for migraine, and we have also shown that the results were consistent after excluding individuals with essential tremor.…”

Section: Discussionmentioning

confidence: 99%

β2‐adrenoceptor agonists and antagonists and risk of Parkinson's disease

et al. 2018

View full text Add to dashboard Cite

Background: β2‐adrenoreceptors have recently been identified as regulators of the α‐synuclein gene, which is implicated in the pathogenesis of Parkinson's disease. Objective: The objectives of this study were to assess the association between use of β2‐agonists and β‐antagonists and the risk of developing PD. Methods: We conducted a nested case‐control study in a cohort of 1,762,164 adults without a diagnosis of PD. They were identified on January, 1, 2004, from the electronic medical records of the largest health care provider in Israel. Participants were followed up until June 30, 2017, for the occurrence of PD. Ten randomly selected controls were matched to each case of PD on age, sex, ethnic group, and duration of follow‐up. Results: During follow‐up 11,314 patients were newly diagnosed with PD and were matched with 113,140 controls. An increased risk of PD was seen with the use of nonselective β‐antagonists (RR, 2.04 [1.90‐2.20]) but not with the use of selective β1‐antagonists (RR, 1.00 [0.95‐1.05]). Use of β2‐agonists was associated with reduced risk of PD (RR, 0.89 [0.82‐0.96] for short‐acting; RR, 0.84 [0.76‐0.93] for long‐acting; and RR, 0.49 [0.25‐0.92] for ultra‐long‐acting β2‐agonists). In an analysis of individual drugs, propranolol and salbutamol were significantly associated with PD risk, even when these drugs were ascertained 5 years prior to the index date, compared with nonusers (RR, 1.31 [1.08‐1.58] and 1.89 {1.53‐2.33]) in patients who filled <6 and ≥6 propranolol prescriptions, respectively; the corresponding RRs for salbutamol were 0.95 (0.83‐1.08) and 0.65 (0.45‐0.94), respectively. Conclusions: Use of propranolol appears to be associated with an increased risk of PD, whereas use of β2‐agonists is associated with a decreased risk of PD. © 2018 International Parkinson and Movement Disorder Society

show abstract

“…This topic has been addressed in the past,1–5 but it is worth revisiting it in view of recently published data related to this subject, including new diagnostic criteria for ET and PD, and additional studies in imaging, epidemiology, pathology, and genetics.…”

Section: Introductionmentioning

confidence: 99%